D-amphetamine compounds, compositions, and processes for making and using the same
AssigneeZevra Therapeutics, Inc.
InventorsSven Guenther, Guochen Chi, Travis Mickle
Life of this patent
Estimating the term…
Abstract
Discloses are d-amphetamine compounds and compositions comprising at least on organic acid covalently bound to d-amphetamine, having the structure of Formula I, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.
Claims52
A method of treating a patient having a disorder or condition requiring stimulation of the central nervous system, of treating a patient having a disease, disorder, or condition mediated by controlling, preventing, limiting, or inhibiting neurotransmitter uptake, or treating a patient having a disease, disorder, or condition mediated by increasing neurotransmitter concentrations in the synapse, the method comprising the step of administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:
- a compound having the structure of Formula I:
- where X is selected from the group consisting of esters, carboxylic acids, amino acids, amino acid residues, amides, and derivatives thereof, and
- Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
- or a pharmaceutically acceptable salt of said compound.
A method of treating a patient having a disorder or condition requiring stimulation of the central nervous system, of treating a patient having a disease, disorder, or condition mediated by controlling, preventing, limiting, or inhibiting neurotransmitter uptake, or treating a patient having a disease, disorder, or condition mediated by increasing neurotransmitter concentrations in the synapse, the method comprising the step of administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:
- a compound has the structure of Formula IB
- where X is selected from the group consisting of esters, carboxylic acids, amino acids, amino acid residues, amides, and derivatives thereof, wherein X is located at the C-2 or C-4 position of the pyridine ring or X is located at two or more of the C-2, C-3, C-4, C-5, or C-6 positions of the pyridine ring, and
- Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
- or a pharmaceutically acceptable salt of said compound.
A method of treating a patient having a disorder or condition requiring stimulation of the central nervous system, of treating a patient having a disease, disorder, or condition mediated by controlling, preventing, limiting, or inhibiting neurotransmitter uptake, or treating a patient having a disease, disorder, or condition mediated by increasing neurotransmitter concentrations in the synapse, the method comprising the step of administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:
- a compound having the structure of Formula IC:
- where X is selected from the group consisting of esters, carboxylic acids, amino acids, amino acid residues, amides, and derivatives thereof, wherein when X is an amide, at least one amide substituent is hydrogen, or at least one amide substituent comprises at least two carbons, and Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.